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The glutathione S-transferases (GSTs) are a family of ubiquitously expressed polymorphic
enzymes important for detoxifying endogenous and exogenous compounds. In addition to
their classic activity of detoxiﬁcation by conjugation of compounds with glutathione, many
other functions are now found to be associated with GSTs.The associations between GST
polymorphisms/functions and human disease susceptibility or treatment outcome, mostly
in adults, have been extensively studied and reviewed.This mini review focuses on studies
related to GST epidemiology and functions related to pediatric cancer. Opportunities to
exploit GST in pediatric cancer therapy are also discussed.
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GENERAL INFORMATION ON GLUTATHIONE
S -TRANSFERASES
THE GST FAMILY
Glutathione S-transferase (GST) isozymes were originally dis-
covered in rat liver cytosol during the early 1960s (Booth et al.,
1961; Coombes and Stakelum, 1961). GSTs are drug-metabolizing
enzymes that catalyze conjugation of glutathione with carcino-
gens, drugs, toxins, or products of oxidative stress. Two distinct
superfamilies of GST isozymes exist (Table 1). One superfamily
comprises cytosolic, soluble, dimeric enzymes. At present, eight
distinct classes have been identiﬁed in this superfamily: alpha,
kappa,mu,omega,pi, sigma, theta, and zeta. Theother superfamily
is composed of microsomal, membrane bound, trimeric pro-
teins. This family of proteins is also called MAPEG (membrane-
associated proteins in eicosanoid and glutathione metabolism;
Hayes and Strange, 2000). While GSTs are expressed in all tissues,
speciﬁc isozyme distribution across different tissues in mammals
is variable and complex (Hiley et al., 1989; Strange et al., 1989).
GST SUBSTRATES
Crystal structures have been determined for many soluble GSTs,
often with bound substrates or products (Oakley, 2011). The
“canonical fold” of a soluble GST subunit reveals an N-terminal
α/β domain forming the GSH-binding site (G-site) and a sec-
ond, α-helical domain forming most of the H-site that binds
the electrophilic substrate (Figure 1). CDNB (1-chloro-2,4-
dinitrobenzene) was initially adopted by biochemists as a “univer-
sal” GST substrate. However, it was soon realized that, although
different transferases may exhibit overlapping substrate speci-
ﬁcities, no common substrate exists that is metabolized by all
GST isozymes (Table 1). Different amino acids in the substrate-
binding site (H-site) of GST isozymes can account for substrate
speciﬁcities. In view of the separate evolutionary histories of
the cytosolic and MAPEG superfamilies, it is not surprising that
they display marked differences in catalytic activities (Armstrong,
1997). Because its binding pocket for electrophiles is hydrophobic,
Microsomal GST1 (MGST1) is uniquely suited among the GSTs
to detoxify reactive intermediates of a more hydrophobic nature
(Schaffert, 2011). The substrate speciﬁcity of individual GST
isozymes suggests that each of them play a unique role in biotrans-
formation of drugs. Genetic variations in these enzymeswill there-
fore inﬂuence the response of individuals to environmental agents.
POLYMORPHISM AND EPIDEMIOLOGY
Genetic polymorphisms in the GST genes arise from nucleotide
alterations that may change codons to generate unique alleles or
even null genotypes. These amino acid substitutions cause steric
changes in the substrate-binding site of the enzyme. As a conse-
quence, the enzymatic activities of GST are signiﬁcantly affected.
Because different GST proteins differ in their ability to catalyze
speciﬁc detoxiﬁcation reactions, polymorphisms inGST will likely
impact response to speciﬁc therapies. Many molecular epidemio-
logical studies have tested associations between polymorphisms of
GST genes and disease susceptibility. The results of such studies
have often been conﬂicting. As a consequence, a number of meta-
analyses have been carried out as part of the Human Genome Epi-
demiology (HuGE) Network, which provided evidence that GST
polymorphisms can result in a small but signiﬁcant increase in
risk of some types of cancers or diseases (Hayes and Strange, 2000;
Bolt and Their, 2006; Di Pietro et al., 2010; Economopoulos and
Sergentanis, 2010; Josephy, 2010;McMahon et al., 2010). However,
most meta-analyses suffered from a serious limitation: fail to dis-
tinguish between heterozygous andhomozygous genotypes,which
resulted in heterogeneity between studies. Now boundaries of the
deletion polymorphisms have been cloned and analytical methods
that assess copy number such as real-time PCR are now available
(Timofeeva et al., 2009). These will be helpful in dissolving some
of the heterogeneity observed in clinical evaluations.
FUNCTIONS OF GST
The classic activity of the GSTs is to detoxify reactive elec-
trophiles by conjugation to glutathione (GSH), thereby reducing
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Table 1 | Human GSTs and their biochemical properties.
Super-family Class Chromo-
some
Gene Protein Substrate Reference
Cytosolic Alpha 6p12.2 GSTA 1 GSTA1-1 CDNB, NBD-Cl, D5AD, PGE2, cholesterol
a-oxide, dibenzo(a,l)pyrene
Hayes and McLellan (1999), Dreij et al.
(2002)
GSTA 2 GSTA2-2 CDNB, NBD-Cl, CuOOH, PGD2 Hayes and McLellan (1999)
GSTA 3 GSTA3-3 Δ5AD, dibenzo(a,l)pyrene Johansson and Mannervik (2001), Dreij
et al. (2002)
GSTA 4 GSTA4-4 HNE, ETA Hayes andMcLellan (1999), Hubatsch et al.
(1998), Balogh et al. (2011)
Cytosolic Mu 1p13.3 GSTM1 GSTM1-1 CDNB, AFB1-epoxide, trans-4-phenyl-3-
buten-2-one, tSO, adrenochrome, aﬂatoxin
B1-8,9-epoxide
Hayes and McLellan (1999), Baez et al.
(1997), Johnson et al. (1997)
GSTM2 GSTM2-2 CDNB, DCNB, cyano DMNG, aminochrome,
dopachrome, noradrenochrome
Hayes and McLellan (1999), Baez et al.
(1997), Norrgard and Mannervik (2011)
GSTM3 GSTM3-3 H2O2, PGH2 Hayes and McLellan (1999), Beuckmann
et al. (2000)
GSTM4 GSTM4-4 n.d.
GSTM5 GSTM5-5 n.d.
Cytosolic Pi 11q13 GSTP1 GSTP1-1 CDNB, acrolein, adenine propenal, thymine
propenal, ETA, 4-vinylpyridine, BPDE,
benzo(c)-phenanthrene, benzo(g)chrysene,
BITC, actin, GSTP, peroxiredoxin VI
Hayes and McLellan (1999), Berhane et al.
(1994), Coles et al. (2000), Hu et al.
(1997a,b,c), Hu et al. (1998), Nakamura
et al. (2000), Tew et al. (2011)
Cytosolic Sigma 4q22.3 GSTS1 GSTS1-1 PGH2 Kanaoka et al. (1997)
Cytosolic Theta 22q11.2 GSTT1 GSTT1-1 NBD-Cl, CuOOH, acrylamide, glycidamide,
EO, CAA, DCM, DBE, EPNP, MB
Huang et al. (1997), Sherratt et al. (1997)
Sherratt et al. (1997), Hayes and McLellan
(1999), Doroshyenko et al. (2009)
GSTT2 GSTT2-2 CuOOH, 1-menaphthyl sulfate Hayes andMcLellan (1999),Tan et al. (1996)
Cytosolic Zeta 14q24.3 GSTZ1 GSTZ1-1 DCA, ﬂuoroacetate, maleylacetoacetate Tong et al. (1998a,b)
Cytosolic Omega 10q24.3 GSTO1 GSTO1-1 MMA, dehydroascorbate, HED,
s-(4-nitrophenacyl)glutathione
Tanaka-Kagawa et al. (2003), Board et al.
(2000, 2008)
Mitochondria
bound
Kappa 7q34-35 GSTK1 GSTK1-1 2-Hydroxychromene-2-carboxylate Robinson et al. (2004)
Micro-
somal
MAPEG 12p12.3
4q28.3
MGST1 MGST1 CDNB,NBD-Cl, 4-nitrobenzyl chloride, Couth Hayes and McLellan (1999)
MGST2 MGST2 CDNB, 5-HPETE, LTA4 Hayes and McLellan (1999), Jakobsson
et al. (1996)
1q23 MGST3 MGST3 5-HPETE, LTA4 Jakobsson et al. (1997)
5 LTC4S LTC4S LTA4 Jakobsson et al. (1996)
13q12 FLAP FLAP Binds to AA and MK-886 Mancini et al. (1993), Mancini et al. (2001)
Modiﬁed from Hayes and Strange (2000). 5-HPETE, 5-hydroperoxyeicosatetraenoic acid; AA, arachidonic acid; BPDE, benzo(a)pyrene diolepoxide; BITC, benzyl isoth-
iocyanate; CAA, chloroacetaldehyde; CDNB, 1-chloro-2,4-dinitrobenzene; CuOOH, cumene hydro-peroxide; DBE, dibromoethane; DCA, dichloroacetic acid; DCM,
dichloromethane; DCNB, 1,2-dichloro-4-nitrobenzene; ?5AD, delta(5)-androstene-3,17(20)-dione; EO, ethylene oxide; EPNP, 1,2-epoxy-3-(p-nitrophenoxy)propane; ETA,
ethacrynic acid; HED, hydroxyethyl disulﬁde; HNE, 4-hydroxynonenal; LTA4, leukotrieneA4;MB,methyl bromide;MMA,mono-methylarsonic acid; n.d., not determined;
tSO, trans-stilbene oxide.
the likelihood of deleterious interactions between such reactive
species and essential cellular components like proteins and nucleic
acids. Knockout and transgenic mouse models were generated for
many GST family members which helped to reveal the physio-
logical function of GST isozymes (Elsby et al., 2003; Henderson
and Wolf, 2011). Based on these and other model systems, many
other activities are now associated with GSTs, including regulation
of signaling pathways and anti-apoptotic activity by GSTP (Tew
et al., 2011), anti- and pro-inﬂammatory functions of sigma-class
GSTs (Flanagan and Smythe, 2011), activities of MGST1 related
to mitochondria (Aniya and Imaizumi, 2011), regulation of the
cardiac muscle ryanodine receptor (Dulhunty et al., 2011), and
functions associated with asthma (Minelli et al., 2010).
GSTs and signaling pathway regulation
It is becoming apparent that GSTP family members participate in
the maintenance of cellular redox homeostasis through a variety
of mechanisms (Tew et al., 2011). GSTP1, for example, displays
an anti-apoptotic activity based on protein–protein interactions
with c-Jun N-terminal kinase (JNK; Adler et al., 1999; Figure 2).
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GSTP1was implicated inmediating S-glutathionylationof speciﬁc
clusters of target proteins and in reactions that play a negative
regulatory role in some kinase pathways through other protein–
protein interactions. GSTP1 has also been implicated in regulat-
ing tumor necrosis factor-alpha (TNF-alpha) signaling primarily
through aphysical associationwith tumornecrosis factor receptor-
associated factor 2 (TRAF2; Wu et al., 2006). In addition, physical
interactions between the HPV16 E7 viral factor and GSTP1 were
found to improve survival capabilities of host cells (Mileo et al.,
2009). GSTA1 is also capable of suppressing JNK signaling caused
by inﬂammatory cytokines or oxidative stress, likely because of the
homology between GST A and P family members, (Romero et al.,
FIGURE 1 | A cartoon diagram of GSTP, a representative of a soluble
GST enzyme.The N-terminal GSH-binding site (G-site, in yellow) and the
C-terminal H-site (in purple) that binds the electrophilic substrate (in orange)
are shown.
2006). It was also reported that GSTM1 binds and inhibits the
activity of Apoptosis Signaling Kinase-1 (ASK1; Cho et al., 2001).
TheGSTM1:ASK1 interaction dissociates under oxidative stress or
heat shock, leading to activation of ASK1 and apoptosis (Dorion
et al., 2002).
MGST1 and its dual function in mitochondria
Microsomal GST1 protects cells (and mitochondria) from oxida-
tive stress by both conjugation and glutathione peroxidase func-
tions (Johansson et al., 2010; Aniya and Imaizumi, 2011; Schaf-
fert, 2011). MCF7 cells overexpressing MGST1 showed protection
against agents that induce peroxidation. Mitochondria in these
cells were shown to be protected from oxidative insult as measured
by calcium loading capacity and respiration. MGST1 also induced
cellular resistance against cisplatin in these cells (Johansson et al.,
2010). In addition to these protective effects, MGST1 also has
deleterious effects that contribute to oxidative stress-induced liver
injury. Preliminary studies indicated that mitochondrial MGST1
was activated by reactive oxygen species (ROS). This activation
led to its aggregation and induction of non-classical mitochon-
drial permeability transition (MPT). MPT induces mitochondrial
dysfunction which results in apoptosis and necrosis. Therefore,
depending on the context, MGST1 activation can either exhibit
a protective or toxic effect on the liver and possibly other tissues
(Schaffert, 2011).
GST IN PEDIATRIC CANCER
EPIDEMIOLOGY
As in adult cancers, a large number of epidemiological studies
have tested possible associations between GST polymorphic vari-
ants as well as deletions with susceptibility of pediatric cancers
(Table 2). GSTM1 is subject to a deletion polymorphism that
is found in as many as 75% of Caucasians (Zhong et al., 1991;
FIGURE 2 | Cartoon model of how GSTP1–JNK and GSTP1–TRAF2
interactions modulate JNK andTNF-α signaling pathways. In
non-stressed cells, GSTP1 form complexes with JNK andTRAF2 respectively.
GSTP1–JNK interaction keeps JNK at low activity, while GSTP1–TRAF2
interaction competes against TRAF2–ASK1 binding which also leads to low
JNK activity. In cells exposed to ROS or TNF-α, GSTP1 dissociates from the
complexes and accumulates as oligomers, with resultant activation of JNK
and downstream signaling pathways.
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Huang et al.,2009).Multiple case-controlled studies have indicated
statistically signiﬁcant associations of the GSTM1 null genotype
with increased risk of childhood cancers. Groups from different
regions in the world found that GSTM1 null genotype related
to increased risk of acute leukemia (ALL and AML) in various
populations (Krajinovic et al., 1999; Davies et al., 2000; Joseph
et al., 2004; Pakakasama et al., 2005; Marino et al., 2009). Ashton
et al. (2007) found that GSTM1 null genotype is associated with
high risk of neuroblastoma in Australia and New Zealand. GSTP1
V105 was found to relate to increased susceptibility to childhood
leukemia in Canada (Krajinovic et al., 2002). However, another
group found that there was no statistically signiﬁcant association
between GSTP1 polymorphism and susceptibility to ALL in Thai
children (Gatedee et al., 2007). Interestingly, one group reported
that GSTO1 A140D and GSTO2 N142D polymorphism were both
signiﬁcantly associated with susceptibility to ALL in Thailand
(Pongstaporn et al., 2009). These conﬂicting results were thought
to be related to differences in ethnicity and age of the patients,
treatment, and follow-up periods included in these studies.
GST AND DRUG RESISTANCE
Glutathione S-transferases have been implicated in the develop-
ment of resistance toward chemotherapeutic agents which lead to
relapse in pediatric cancers (Table 2). GSTT1 null genotype has
been shown to confer a reduced risk of relapse in childhood ALL
in several case studies (Anderer et al., 2000; Stanulla et al., 2000).
However, theGSTT1null genotypewas also shown tobe associated
with an increased risk of death after chemotherapy in childhood
AML (Davies et al., 2001). As to the GSTM1–GSTT1 double-null
genotype, one group reported an increased risk of early relapse of
ALL with double-null genotype (Takanashi et al., 2003) while a
subsequent study reported the opposite result (Kham et al., 2004).
Yet other studies showed that the double-null genotype was not
associated with risk of relapse or treatment outcome inALL (Chen
et al., 1997;Davies et al., 2002; Balta et al., 2003; Jazbec et al., 2003).
GSTP1 expression was signiﬁcantly increased in relapsed AML,
and GSTP1 V105 was found to be related to increased relapse rate
of childhood leukemia (Sauerbrey et al., 1994; Beck et al., 1996;
Zielinska et al., 2004).
Several studies using microarray technology have identiﬁed
glutathione metabolism pathway to reﬂect tumor resistance to
chemotherapy in Ewing’s sarcoma. The authors found that the
expression of MGST1 clearly predict Ewing’s sarcoma prog-
nosis and to be associated with doxorubicin chemosensitivity
(Townsend and Tew, 2003; Schaefer et al., 2008; Scotlandi et al.,
2009). In a separate microarray analysis for target genes of
EWS/FLI, the master regulator of Ewing’s sarcoma, GSTM4 was
found to be upregulated by EWS/FLI. Reduction of GSTM4 lev-
els resulted in an increased sensitivity of Ewing’s sarcoma cells to
chemotherapeutic agents (etoposide and fenretinide). This sug-
gested a role for GSTM4 in drug resistance. In support of this
hypothesis, patients with Ewing’s sarcoma whose tumors had
higher levels of GSTM4 expression hadworse outcomes than those
with lower expression levels (Luo et al., 2009).
GSTM1 has been reported to be a signiﬁcant risk factor for
hematologic relapse in childhood ALL. Transduction of GSTM1
into T-acute lymphoblastic leukemia cells selectively decreased
cellular sensitivity to dexamethasone in a manner that was inde-
pendent of glutathione conjugation, but was due to apoptosis
inhibition. Interestingly, p38-MAPK and Bim activation were
suppressed, and NF-kappaB p50 was activated, in these GSTM1
expressing cells. The authors proposed that GSTM1 is a novel
regulator of dexamethasone-induced apoptosis, and causes dex-
amethasone resistance by suppression of Bim through dual mech-
anismsof downregulationof p38-MAPKandup-regulationof NF-
kappaB p50 (Hosono et al., 2010). Consistently,GSTM1null geno-
type was associated with a reduced risk of relapse in ALL (Stanulla
et al., 2000). Association of GSTM1 with resistance to adriamycin
and cisplatin was also found in childhood hepatoblastoma (Bader
et al., 1998).
Drug resistance is a common problem in the treatment of
childhood rhabdomyosarcoma (RMS). To identify causes of drug
resistance in this disease, Seitz et al. (2010) performed gene expres-
sion analysis of tumors from mice transplanted with embryonal or
alveolar RMS cells and treated with vincristine. The authors found
2314 differentially expressed genes between the groups in alveolar
RMS and 1387 in embryonal RMS. Pathway analysis revealed a
cluster of ﬁve overexpressed genes of the GST family in animals
treated with vincristine, suggesting a cause for drug resistance.
In vitro experiments conﬁrmed up-regulation of GST activity fol-
lowing incubation with doxorubicin and topotecan in RMS cell
lines. Incubation with GST inhibitors resulted in a decreased cell
viability. The authors concluded that reversal of drug resistance
in childhood RMS may be achieved by GST inhibitors, at least
in part. Thus, the GST family represents a promising target for
further treatment strategies in childhood RMS (Seitz et al., 2010).
The association of GSTs with risk of relapse and drug resis-
tance may not be a straightforward reﬂection of their ability to
participate in detoxiﬁcation reactions. Greater understanding of
the numerous factors affecting GST expression and activity, as
well as GST functions, may reveal further connections between
GST and individual responses to disease and drugs.
REGULATION OF GST
Most cases of Ewing’s sarcoma express the EWS/FLI fusion onco-
protein (Turc-Carel et al., 1988). EWS/FLI functions as an aberrant
transcription factor that mediates the transformed phenotype
through the deregulation of several key target genes (Kinsey et al.,
2006; Owen and Lessnick, 2006; Smith et al., 2006; Tirado et al.,
2006; Luo et al., 2009). Furthermore, EWS/FLI has been shown to
transcriptionally activate some of its gene targets through GGAA-
containing microsatellite promoter elements (Gangwal et al.,
2008). Interestingly, GSTM4 contains a GGAA-microsatellite in
its promoter. In vitro and in vivo studies revealed that EWS/FLI
binds to the microsatellite and up-regulates GSTM4 via this ele-
ment.Otherworkhas shown that the ability of EWS/FLI to activate
gene expression through GGAA-microsatellite response elements
is proportional to the length of the microsatellite, suggesting that
microsatellite polymorphisms might affect target gene expression
(Gangwal et al., 2010). Indeed, this hypothesis was supported by
theﬁnding that the number of GGAArepeats present in theNR0B1
promoter positively correlated with the level of NR0B1 mRNA
expression in Ewing’s cells (Garcia-Aragoncillo et al., 2008). Fur-
ther work will be needed to determine if a similar relationship
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exists for the GSTM4 gene, and if such a relationship correlates
with drug resistance in Ewing’s sarcoma.
The GGAA-microsatellite is not shared by other GST family
members, however. Other GST promoters contain response ele-
ments such as an antioxidant response element and a xenobiotic
response element, as well as putative binding sites for transcrip-
tion factors such as AP-1, MAF, Nrf1, Jun, Fos, and NF-kappaB.
Such complex response elements suggest a mechanism for differ-
ential regulation of GST isozymes across tumor types in response
to differing toxic insults.
GST AS TARGETS IN PEDIATRIC CANCER TREATMENT
The design and discovery of compounds that bind GST isozymes
and modulate their biological activity has become an important
aim in cancer research because GST isozymes are overexpressed in
many cancer cell lines (Tew et al., 1996), and induce drug resistance
by inactivating many chemotherapeutic compounds via GSH con-
jugation (Tew et al., 1997). There are a number of candidate
GST-targeted drugs at various stages of preclinical development
(Tew et al., 1997; Ruzza and Quintieri, 2009; Wondrak, 2009; Sau
et al., 2010). Ethacrynic acid, an inhibitor that lacks class speciﬁcity
for GSTs, represented a ﬁrst attempt in this direction; however, its
low afﬁnity and deleterious side effects have discouraged its use
in clinical practice (Tew et al., 1997). More recently, GSH pep-
tidomimetic compounds have been designed, including TER 199
(Figure 3). However, many GSH derivatives are actively extruded
from cancer cells by speciﬁc export pumps, such as the multidrug
resistance protein, and so are unlikely to be highly efﬁcacious
(Muller et al., 1994; Morgan et al., 1996).
A new class of GST inhibitors, called NBD derivatives, has been
designed recently (Ricci et al., 2005). A representative of this class
is NBDHEX, which interacts with GSTP1 and triggers apoptosis
in human tumor cells through dissociation of the JNK–GSTP1
complex (Turella et al., 2005; Figure 3). Osteosarcoma, Ewing’s
sarcoma, and rhabdomyosarcoma cell lines were all found to be
sensitive to NBDHEX in vitro and in xenograft models (Scotlandi
et al., 2009; Pasello et al., 2011). Importantly, NBDHEX was not
extruded from tumor cells by multidrug resistance protein pumps
(Ricci et al., 2005; Turella et al., 2005, 2006). NBDHEX had syn-
ergistic effect with doxorubicin, vincristine, cisplatin in an in vitro
study. In vivo studies conﬁrmed the cytostatic efﬁcacy of NBD-
HEX and its synergy with vincristine in Ewing’s sarcoma cells, and
also its effect against the metastatic spread of osteosarcoma cells
(Pasello et al., 2011). Although NBDHEX is still under preclin-
ical in vivo evaluation, it may be an interesting new therapeutic
option for patients who are not highly responsive to conventional
regimens.
Another approach is to design prodrugs that exploit the high
GST expression levels found in drug resistant tumors and cells.
Prodrugs would be preferentially activated by GST in malignant
cells, thus sparing normal tissues and enhancing the therapeutic
index. JS-K is a member of the O2-aryl diazeniumdiolate com-
pound family which was designed to release nitric oxide (NO)
when activated by GSTs (Shami et al., 2006). JS-K has shown
promise as a novel cancer therapeutic agent in a number of stud-
ies. For instance, JS-K selectively induces programmed cell death
in breast cancer cells while sparing normal mammary epithelial
cells under the same conditions (McMurtry et al., 2011; Figure 3).
The selective anti-tumor activity of JS-K warrants its further
investigation in pediatric cancers.
CONCLUSION
Many epidemiological studies have investigated possible associa-
tions between GST polymorphisms with risk of pediatric cancers.
Some studies have indicated increased risk for speciﬁc genotypes,
such as the GSTT1 and GSTM1 deletions, while other studies
have not conﬁrmed this association. These conﬂicting results need
to be interpreted with caution. Many GST activities other than
detoxiﬁcation have been discovered and may contribute to dif-
ferent GST activities among individuals. GSTs have also been
implicated in the development of resistance toward chemother-
apeutic drugs. Although further studies are required to reveal the
underlying mechanisms, drugs targeting GSTs have been designed
to overcome resistance to conventional therapeutic agents. Little
FIGURE 3 | GST as targets in pediatric cancer treatment. GST non-speciﬁc
inhibitors such as ETA or TER199 decrease the GST activity in tumors and
sensitize tumor cells to chemotherapeutic agents. NBDHEX treatment of
tumor cells interrupts GSTP1–JNK interaction which releases and activates
JNK and results in tumor cell apoptosis. Prodrugs such as J-SK is activated
speciﬁcally in tumors with high GST activity and selectively kills tumor cells.
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progress has beenmade in understanding howGST expression and
activity is regulated. Such studies will allow an understanding of
the upstream players in the glutathione metabolism pathway and
provide potential new approaches for the treatment of pediatric
cancers.
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